Price of this breast cancer drug reduced

Despite its effectiveness, the high cost of Trastuzumab has posed a significant financial barrier for many patients in India.

150
medicine Drugs Tablets Pills
Picture: Pixabay

Last Updated on January 6, 2024 by The Health Master

Breast cancer drug

Bengaluru-based pharmaceutical company, Glenmark Pharmaceuticals, has announced a significant price reduction for Trumab, a drug used in the treatment of HER2-positive breast cancer.

Marketed in India, Trumab’s 440 mg vial will now be available at a price of Rs 15,749.

This price reduction positions Trumab as the most affordable option for HER2-positive breast cancer patients in the country.

The Importance of Trastuzumab in HER2-Positive Breast Cancer Treatment:

Trastuzumab, a monoclonal antibody, has long been considered a crucial treatment option for HER2-positive breast cancer patients.

Despite its effectiveness, the high cost of Trastuzumab has posed a significant financial barrier for many patients in India.

Glenmark’s Commitment to Accessibility:

Alok Malik, Executive Vice President and Head of India Formulations at Glenmark Pharmaceuticals Ltd., highlighted the company’s dedication to improving access to quality healthcare.

By reducing the price of Trumab, Glenmark aims to provide hope and accessibility to over 75 percent of self-paying HER2-positive breast cancer patients in India.

Understanding HER2 and its Role in Breast Cancer:

HER2, also known as human epidermal growth factor receptor 2, is a protein overexpressed in breast cells and is tested for during diagnosis.

HER2 proteins play a critical role in regulating cell growth and division. Breast cancer that is HER2-positive tends to grow rapidly, spread, and recur.

Trastuzumab functions by binding to the HER2 protein, effectively blocking its activity and inhibiting the growth and spread of cancer cells.

Breast Cancer Statistics in India:

According to the GLOBOCAN 2020 report, breast cancer is the most commonly diagnosed cancer in India, accounting for 13.5 percent of all cases.

Each year, an estimated 1.78 lakh new cases of breast cancer are diagnosed in the country, with a 5-year prevalence of 4.5 lakh cases.

Conclusion:

By reducing the cost of Trumab, Glenmark Pharmaceuticals aims to improve accessibility and affordability for HER2-positive breast cancer patients in India, providing them with a more viable treatment option.

This step not only demonstrates Glenmark’s commitment to quality healthcare but also brings hope to patients battling this challenging disease.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news